StockIQ.techJohnson & Johnson (JNJ) Stock Analysis
Free AI-powered analysis and research for Johnson & Johnson stock
Sector: Healthcare
JNJ snapshot
Data as of 3 Nov 2026 close. Updated daily.
Johnson & Johnson scores 67/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 85% of its 52-week range, up 43.8% over the past year. Latest reported figures show a profit margin of 16.2%, return on equity of 20.0% and revenue growth of +5.9%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +2
- MACD Bullish: +8
- High P/E (41.5): -10
- Good Profit Margin (16.2%): +5
- Weak Liquidity (1.02 Current Ratio): -5
- Excellent ROE (20.0%): +8
- High P/B (8.07): -5
- Above MA200: +4
- Strong Momentum (+43.8% over 1 year): +8
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full JNJ report
Johnson & Johnson (JNJ) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze JNJ Now →📰 Latest Update
Johnson & Johnson (JNJ) Stock Gets Fair Value Bump On Mixed Analyst Target Changes
Fri, October 23, 2026 at 2:13 PM UTC 4 min read
Johnson & Johnson (JNJ) received a fair value adjustment following mixed changes in analyst price targets. This update reflects varying investor sentiment and expectations regarding the company's future performance, which could influence stock valuation and trading behavior. For investors, this indicates a potential opportunity to reassess their positions based on the analysts' insights and the company's market outlook.